Charles Szabo, MD
Epilepsy · San Antonio, TXNPI 1548277866
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,003 of the $14,932 with a category attached, or 67.0%. UCB, Inc. accounts for 69.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $7,255 and has fallen 96.4% since, to $262 in 2025. Among epilepsy clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $169.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$10K
- Livanova USA, Inc.$2K
- Neuropace, Inc.$1K
- Eisai Inc.$374
- Neurelis, Inc.$365
- SK Life Science, Inc.$312
- plus $714 from 8 others
Across 11 payments — averaging $4891.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$36K
- Livanova USA, Inc.$18K
What the payments were for
- Consulting fees$7505%
- Speaking & faculty fees$10,00367%
- Travel & lodging$8226%
- Food & beverage$3,35822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 28 | $10,319 |
| Livanova USA, Inc. | 5 | $1,728 |
| Neuropace, Inc. | 7 | $1,121 |
| Eisai Inc. | 15 | $374 |
| Neurelis, Inc. | 9 | $365 |
| SK Life Science, Inc. | 8 | $312 |
| Jazz Pharmaceuticals Inc. | 3 | $212 |
| Greenwich Biosciences, Inc. | 4 | $205 |
| Immedica Pharma US, Inc. | 1 | $125 |
| Otter Pharmaceuticals, LLC | 3 | $91 |
| Aquestive Therapeutics, Inc. | 2 | $36 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Zogenix Inc. | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Briviact$6,576
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$1,626
- RNS Neurostimulator Kit$1,037
- Epidiolex$252
- Fycompa$125
- XCOPRI$125
- ZTALMY$125
- VALTOCO$103
How this compares
$14,932 in reported general payments places this provider in the 90th percentile of 36 epilepsy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 62 | $330,795 |
| BriviactBrivaracetam | 123 | $226,607 |
| XcopriCenobamate | 137 | $201,143 |
| OnfiClobazam | 35 | $118,353 |
| VimpatLacosamide | 53 | $79,234 |
| AptiomEslicarbazepine Acetate | 18 | $63,252 |
| KeppraLevetiracetam | 16 | $52,731 |
| Lacosamide | 231 | $48,910 |
| SympazanClobazam | 12 | $46,365 |
| FycompaPerampanel | 30 | $37,389 |
| Rufinamide | 40 | $34,994 |
| FelbatolFelbamate | 20 | $33,992 |
| Clobazam | 185 | $26,006 |
| NayzilamMidazolam | 25 | $25,442 |
| Tiagabine Hcl | 14 | $11,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $10,319 | $331,283201 claims |
| SK Life Science, Inc.Xcopri | $312 | $201,143137 claims |
| Aquestive Therapeutics, Inc.Sympazan | $36 | $46,36512 claims |
| Eisai Inc.Fycompa | $374 | $37,38930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 36 epilepsy providers in Texas.
Other epilepsy in San Antonio
- Linda LearySan Antonio$9K
- Gustavo Charria-OrtizSan Antonio$3K
- Diep BuiSan Antonio$3K
- Sreekanth KoneruSan Antonio$3K
- Octavian LieSan Antonio$721
- Karen KeoughAustin$474K
- Katherine LabinerAustin$163K
- Jay HarveyDallas$19K
- Daniel GustkeyAustin$12K
- Erin FiedlerDallas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.